Thus, drugs that specifically target the TGFβ pathway at different levels (i.e., maturation of latent TGFβ to active TGFβ dimers, ligand binding to its receptors, TβRI kinase activity) have been or are currently tested for possible anti-tumor effects in different cancers, including liver cancers [100,101,102,103,104]. The gene discussed is TGFB1; the disease is cancer.